Abstract
Objective
N-acetylcysteine (NAC) is a mucolytic agent with anti-oxidant properties. It might have potential positive effects in renal patients and, therefore, its pharmacokinetics and safety in haemodialysis was investigated.
Methods
Twelve dialysis patients received 2 g NAC (10 ml NAC 20% solution i.v.) mixed with 500 ml saline during the first 3 h of the session for six dialysis sessions. A bolus of heparin was injected intravenously as LWH-heparin. In six patients, one session was repeated with NAC mixed with heparin and infused through the heparin pump.
Results
Baseline NAC was on average 454 ng ml−1; its concentration increased to 9,253 ng ml−1 at the second infusion and attained a steady state between 14,000 ng ml−1 and 17,000 ng ml−1 at the fourth dose. We observed a C max of 53,458 ng ml−1 with a t max of 3.0 h. Plasma clearance was 1.25 l h−1 and dialytic clearance 5.52 l h−1. No side effects were observed.
Conclusion
In the case of repeated doses, the NAC pre-dose concentration after repeated infusion of 2 g of the drug during the first 3 h of a dialysis session reached the steady state at the fourth infusion, without further accumulation. The dialytic clearance is effective, the total body clearance being reduced to 1.25 l h−1. In dialysis patients, 2 g NAC given intravenously over 3 h is a safe dosage, with no short-term side effects.
Similar content being viewed by others
References
Lindner A, Charra B, Sherrand DJ, Scribner BH (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697–701
Hakim R (1993) Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44:484–494
Alvarez V, Pulido R, Companero MR et al (1991) Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 40:899–905
Amaout M, Hakim R, Todd R et al (1985) Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312:457–462
Kuwahara T, Markert M, Wauters JP (1988) Neutrophil oxygen radical production by dialysis membranes. Nephrol Dial Transplant 3:661–665
Nguyen AT, Lethias C, Zingraff J et al (1985) Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within micro amounts of whole blood. Kidney Int 28:158–167
Kolb G, Noiting C, Eckle I et al (1985) The role of membrane contact in hemodialysis-induced granulocyte activation. Nephron 57:64–68
Hirnmelfarb J, Ault KA, Holbrook D et al (1993) Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 4:178–186
Becker BN, Himmelfarb J, Henrich WL et al (1997) Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475–486
Boaz M, Matas Z, Biro A et al (1999) Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 56:1078–1083
Suliman ME et al (2000) Hyperhomocysteinemia. Nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 57:1727–1735
Martindale (1999) The complete drug reference, 32nd edn. K. Parfitted, pp 1052–1054
Santangelo F, Witko-Sarsat V, Drüeke T, Descamps-Latscha B (2004) Restoring glutathione as a therapeutic strategy in chronic kidney disease. Nephrol Dial Transplant 19:1951–1955
Tepel M, Van der Giet M, Statz M, Jankowski J, Zidek W (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 107:992–995
Holdiness MR (1991) Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 20:123–134
Jones AL, Jarvie DR, Simpson D, Hayes PC, Prescott LF (1997) Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther 11(4):787–791
Tepel M, Van der Giet M, Schwarzfeld C, Laufer U, Liermann D (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184
Durham JD, Caputo C, Dokko J et al (2002) A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62:2202–2207
Allaqaband S, Tumuluri R, Malik AM et al (2002) Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57:279–283
Pannu N, Manns B, Lee H, Tonelli M (2004) Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65:1366–1374
Drüeke TB, Descamps-Latscha B, Locatelli F (2003) Stopping a medical research project for financial reasons. Nephrol Dial Transplant 18:1982–1983
Acknowledgements
We are grateful to Zambon Group S.p.A., Bresso, Milan, Italy, for assistance in the preparation of the protocol, supply of the necessary vials of N-acetylcysteine and financial support. We also thank Mrs Monia Fibbioli Crivelli for helping with data analysis.
Author information
Authors and Affiliations
Corresponding author
Additional information
The study was conducted in accordance with the guidelines for Good Clinical Practice and all current Swiss laws concerning clinical research. The protocol was approved by the Ethics Committee of the Canton Ticino, Switzerland.
Rights and permissions
About this article
Cite this article
Soldini, D., Zwahlen, H., Gabutti, L. et al. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur J Clin Pharmacol 60, 859–864 (2005). https://doi.org/10.1007/s00228-004-0850-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0850-0